ArticleCancer discoveryPublished
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
Regional connection
Verified An author affiliation on the Europe PMC record names Thomas Jefferson University. Affiliation source
- Institution
- Thomas Jefferson University
- County
- Philadelphia County
Publication record
- Type
- Article
- Venue
- Cancer discovery
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Prostate-Specific Antigen; Oxidoreductases; Antigens, Neoplasm; Treatment Outcome; Immunotherapy; Male; Prostatic Neoplasms, Castration-Resistant
- PubMed ID
- 37861461
- PubMed Central ID
- PMC10784743
- Open access
- Yes, open
- Added to directory
- Source checked